drugset
drugset / Trial / NCT00501969

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

NCT00501969 ↗

Phase 3 Completed 395 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with advanced-stage idiopathic Parkinson's disease

Timeline

Start
2004-08
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 4 mg Other
Subject Rotigotine Unknown 6 mg Other
Subject Rotigotine Unknown 8 mg Other
Subject Rotigotine Unknown 10 mg Other
Subject Rotigotine Unknown 12 mg Other
Subject Rotigotine Unknown 14 mg Other
Subject Rotigotine Unknown 16 mg Other

Indications

Parkinson disease